Research News

SGI-110 is an Ovarian Cancer Chemosensitizer

(February 4, 2014)  In research published last October in Clinical Cancer Research, a team of OCRF-funded investigators showed that a novel therapy can resentisize ovarian cancer to chemotherapy.  The work was led by Dr…

Read on

OCRF Research Identifies Six New Susceptibility Loci for Ovarian Cancer

(Feb. 3, 2015) An international study using data from the OCRF-funded Ovarian Cancer Association Consortium has found six new gene regions which increase a woman’s risk of ovarian cancer…

Read on

Population Study Shows Salpingectomy Decreases Risk of Ovarian Cancer

(Feb. 2, 2015) Recent studies have suggested that ovarian cancer predominantly arises within the fallopian tubes or the uterus…

Read on

OCRF Research Pinpoints Two Genes that Trigger Ovarian Cancer

(January 28, 2015) OCRF grantee Ron Chandler, PhD developed a mouse model of clear cell ovarian cancer and found a potential route to better treatments and much-needed diagnostic screens. Dr…

Read on

Veliparib Trial Fails to Improve Outcomes in Ovarian Cancer

(January 26, 2015) Use of the PARP inhibitor veliparib in combination with oral cyclophosphamide did not result in an improvement in response rate or median progression-free survival compared with treatment with cyclophosphamide alone, according to…

Read on

BRCA1/2 Mutations and 10 year Survival in Ovarian Cancer

(January 22, 2015) In a study published in Clinical Cancer Research, researchers analyzed the effect of germline mutations in BRCA1 and BRCA2 on mortality in ovarian cancer patients up to ten years after diagnosis…

Read on

Ovarian Cancer Will Continue to be Sequenced After The Cancer Genome Atlas Ends

The Cancer Genome Atlas (TCGA), a massive U.S. effort to genetically profile 10,000 tumors, has officially come to an end…

Read on

Palliative Care Consultation Improves Symptoms in Gynecologic Cancer Patients

A new study published in Gynecologic Oncology found that palliative care consultation is associated with improvement in symptom burden, the majority of which occurs within one day of consultation…

Read on

FDA Approves Olaparib for Ovarian Cancer

(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly ADP-ribose polymerase) inhibitor class…

Read on

Under the Microscope: OCRF’s 2014 Research Progress Report

(12/14/14) | In 2014, with your generous support OCRF grantees made significant advances in the fight against ovarian cancer, including: Identified a biomarker that may predict treatment response Shed new light on ovarian cancer metastasis…

Read on

OCRF Research Shows Targeting microRNA May Benefit Some Ovarian Cancer Patients

(December 10, 2014) OCRF Ann Schreiber Mentored Investigator Award Grantee, Pradeep Chaluvally-Raghavan, Ph.D…

Read on

Population Screening for BRCA Mutations in Ashkenazi Jewish Women is Cost-Effective

Population-based testing for BRCA 1/2 gene mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing…

Read on